Literature DB >> 7552712

Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir.

D G Brown1, R Visse, G Sandhu, A Davies, P J Rizkallah, C Melitz, W C Summers, M R Sanderson.   

Abstract

The crystal structures of thymidine kinase from herpes simplex virus type-1 complexed with its natural substrate deoxythymidine (dT) and complexed with the guanosine analogue Ganciclovir have been solved. Both structures are in the C222(1) crystal form with two molecules per asymmetric unit related by a non-crystallographic two-fold axis. The present models have been refined to 2.8 A and 2.2 A, with crystallographic R factors of 24.1% and 23.3% for the dT and Ganciclovir complexes respectively, without the inclusion of any solvent molecules. The core of the molecule exhibits high structural homology with adenylate kinase and other nucleotide binding proteins. These structural similarities provide an insight into the mechanism of nucleoside phosphorylation by thymidine kinase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552712     DOI: 10.1038/nsb1095-876

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  26 in total

1.  Replication fidelity of the supF gene integrated in the thymidine kinase locus of herpes simplex virus type 1.

Authors:  Ying T Hwang; Bu-Yuan Liu; Charles B C Hwang
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Mutation spectra of herpes simplex virus type 1 thymidine kinase mutants.

Authors:  Qiaosheng Lu; Ying T Hwang; Charles B C Hwang
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 3.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Cloning and expression of human deoxyguanosine kinase cDNA.

Authors:  M Johansson; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  Low-level expression and reversion both contribute to reactivation of herpes simplex virus drug-resistant mutants with mutations on homopolymeric sequences in thymidine kinase.

Authors:  Anthony Griffiths; Malen A Link; Caroline L Furness; Donald M Coen
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Structures of thymidine kinase 1 of human and mycoplasmic origin.

Authors:  Martin Welin; Urszula Kosinska; Nils-Egil Mikkelsen; Cecilia Carnrot; Chunying Zhu; Liya Wang; Staffan Eriksson; Birgitte Munch-Petersen; Hans Eklund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

7.  Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia.

Authors:  Michael I Besecker; Caroline L Furness; Donald M Coen; Anthony Griffiths
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

8.  Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair.

Authors:  F Alaee; O Sugiyama; M S Virk; H Tang; H Drissi; A C Lichtler; J R Lieberman
Journal:  Gene Ther       Date:  2013-11-28       Impact factor: 5.250

9.  Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging.

Authors:  Vladimir Ponomarev; Michael Doubrovin; Inna Serganova; Tatiana Beresten; Jelena Vider; Aleksander Shavrin; Ludmila Ageyeva; Julius Balatoni; Ronald Blasberg; Juri Gelovani Tjuvajev
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

10.  Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia.

Authors:  Kening Wang; Gowtham Mahalingam; Susan E Hoover; Erik K Mont; Steven M Holland; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.